Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Genentech, Inc. Drug Patent Portfolio

Genentech, Inc. owns 6 purple book drugs protected by 63 US patents with Herceptin having the least patent protection, holding only 1 patent. And Actemra with maximum patent protection, holding 35 patents. Given below is the list of Genentech, Inc.'s drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12030959 Anti-IgE antibody therapy for multiple food allergies 20 Jul, 2043
Active
US10112994 Methods of producing two chain proteins in bacteria 05 Nov, 2035
Active
US10336983 Method for increasing the specific production rate of eukaryotic cells 31 Jul, 2035
Active
US10208355 Method of treatment for glioblastoma by administering a VEGF antagonist 14 Jul, 2035
Active
US10274466 Elucidation of ion exchange chromatography input optimization 11 Jul, 2035
Active
US10017732 Cell culture compositions with antioxidants and methods for polypeptide production 25 Dec, 2034
Active
US9441035 Cell culture media and methods of antibody production 23 Apr, 2034
Active
US10676710 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
Active
US10829732 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
Active
US9765379 Harvest operations for recombinant proteins 10 Mar, 2034
Active
US10906934 Protein purification methods 12 Oct, 2033
Active
US10421984 Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele 19 Sep, 2033
Active
US9630988 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 13 Jun, 2033
Active
US10590164 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 19 Mar, 2033
Active
US10513697 CO2 profile cultivation 17 Sep, 2032
Active
US9750752 Subcutaneously administered anti-IL-6 receptor antibody 30 Aug, 2032
Active
US9539263 Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis 23 May, 2032
Active
US10874677 Subcutaneously administered anti-IL-6 receptor antibody 02 Mar, 2032
Active
US9487809 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 14 Jan, 2032
Active
US10231981 Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis 03 Dec, 2031
Active
US11667720 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
Active
US8580264 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
Active
US10704071 Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 18 Aug, 2031
Active
US10662237 Method to improve virus filtration capacity 07 Aug, 2031
Active
US10011856 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 26 May, 2031
Active
US8512983 Production of proteins in glutamine-free cell culture media 04 Jan, 2031
Active
US10501769 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US11021728 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US11136610 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US11377678 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
Active
US10982003 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
Active
US9714293 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
Active
US8568720 High concentration antibody-containing liquid formulation 05 Nov, 2029
Active
US8460895 Method for producing recombinant proteins with a constant content of pCO2 in the medium 08 Aug, 2029
Active
US11136375 Method for production of antibody 19 Jul, 2029
Active
US11008394 High concentration antibody-containing liquid formulation 26 Dec, 2028
Active
US11359026 High concentration antibody-containing liquid formulation 26 Dec, 2028
Active
US11584798 High concentration antibody-containing liquid formulation 26 Dec, 2028
Active
US11078294 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US8574869 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US10906986 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US10808037 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US10759866 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US11987637 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
Active
US8398980 Subtypes of humanized antibody against interleukin-6 receptor 25 Feb, 2028
Active
US10450379 Method for treating joint damage 14 Nov, 2026
Active
US10654940 Method for treating joint damage 14 Nov, 2026
Active
US8617550 Treatment of vasculitis with IL-6 antagonist 03 Mar, 2026
Active
US10034940 High concentration antibody and protein formulations 04 Nov, 2025
Active
US7976838 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor 30 Jun, 2025
Active
US9902777 Methods for producing subtypes of humanized antibody against interleukin-6 receptor 28 May, 2025
Active
US8734800 Subtypes of humanized antibody against interleukin-6 receptor 24 Mar, 2025
Active
US7485704 Reducing protein A leaching during protein A affinity chromatography 08 Mar, 2025
Active
US8709409 Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate 22 Jun, 2024
Active
US9795672 Treatment with anti-VEGF antibodies 28 May, 2024
Active
US10744201 Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate 28 Apr, 2024
Active
US7521052 Methods for treating interleukin-6 related diseases 28 Apr, 2024
Active
US8383773 Protein product and method for reducing biomass-biomass interactions 13 Dec, 2023
Active
US6921659 Protease-deficient cells 17 Oct, 2023
Active
US7332289 Method of purifying protein 04 Aug, 2023
Active
US9688775 System for antibody expression and assembly 31 Dec, 2022
Active
US6828121 Bacterial host strains 08 Jul, 2022
Active
US6716602 Metabolic rate shifts in fermentations expressing recombinant proteins 01 Nov, 2021
Active


Genentech, Inc.'s Family Patents


Family Patents



Genentech, Inc. Drug List

Given below is the complete list of Genentech, Inc.'s drugs and the patents protecting them.


1. Actemra

Actemra is protected by 35 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10336983 Method for increasing the specific production rate of eukaryotic cells 31 Jul, 2035
(10 years from now)
Active
US10017732 Cell culture compositions with antioxidants and methods for polypeptide production 25 Dec, 2034
(10 years from now)
Active
US10676710 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
(9 years from now)
Active
US10829732 Cell culture compositions with antioxidants and methods for polypeptide production 14 Mar, 2034
(9 years from now)
Active
US9630988 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 13 Jun, 2033
(8 years from now)
Active
US10590164 Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration 19 Mar, 2033
(8 years from now)
Active
US9750752 Subcutaneously administered anti-IL-6 receptor antibody 30 Aug, 2032
(7 years from now)
Active
US9539263 Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis 23 May, 2032
(7 years from now)
Active
US10874677 Subcutaneously administered anti-IL-6 receptor antibody 02 Mar, 2032
(7 years from now)
Active
US10231981 Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis 03 Dec, 2031
(6 years from now)
Active
US11667720 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
(6 years from now)
Active
US8580264 Subcutaneously administered anti-IL-6 receptor antibody 07 Nov, 2031
(6 years from now)
Active
US10662237 Method to improve virus filtration capacity 07 Aug, 2031
(6 years from now)
Active
US8512983 Production of proteins in glutamine-free cell culture media 04 Jan, 2031
(6 years from now)
Active
US10501769 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(5 years from now)
Active
US11021728 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(5 years from now)
Active
US11136610 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(5 years from now)
Active
US11377678 Method for the production of a glycosylated immunoglobulin 25 Oct, 2030
(5 years from now)
Active
US10982003 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
(5 years from now)
Active
US9714293 Production of proteins in glutamine-free cell culture media 06 Aug, 2030
(5 years from now)
Active
US8568720 High concentration antibody-containing liquid formulation 05 Nov, 2029
(4 years from now)
Active
US11136375 Method for production of antibody 19 Jul, 2029
(4 years from now)
Active
US11008394 High concentration antibody-containing liquid formulation 26 Dec, 2028
(4 years from now)
Active
US11359026 High concentration antibody-containing liquid formulation 26 Dec, 2028
(4 years from now)
Active
US11584798 High concentration antibody-containing liquid formulation 26 Dec, 2028
(4 years from now)
Active
US11078294 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(3 years from now)
Active
US8574869 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(3 years from now)
Active
US8398980 Subtypes of humanized antibody against interleukin-6 receptor 25 Feb, 2028
(3 years from now)
Active
US8617550 Treatment of vasculitis with IL-6 antagonist 03 Mar, 2026
(1 year, 2 months from now)
Active
US9902777 Methods for producing subtypes of humanized antibody against interleukin-6 receptor 28 May, 2025
(4 months from now)
Active
US8734800 Subtypes of humanized antibody against interleukin-6 receptor 24 Mar, 2025
(2 months from now)
Active
US8709409 Method for treating rheumatoid arthritis by administering an anti-IL-6 antibody and methotrexate 22 Jun, 2024
(6 months ago)
Expired
US10744201 Method for treating rheumatoid arthritis with a human IL-6 receptor antibody and methotrexate 28 Apr, 2024
(7 months ago)
Expired
US7521052 Methods for treating interleukin-6 related diseases 28 Apr, 2024
(7 months ago)
Expired
US7332289 Method of purifying protein 04 Aug, 2023
(1 year, 4 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Actemra's drug page


2. Avastin

Avastin is protected by 12 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10208355 Method of treatment for glioblastoma by administering a VEGF antagonist 14 Jul, 2035
(10 years from now)
Active
US10274466 Elucidation of ion exchange chromatography input optimization 11 Jul, 2035
(10 years from now)
Active
US9441035 Cell culture media and methods of antibody production 23 Apr, 2034
(9 years from now)
Active
US10906934 Protein purification methods 12 Oct, 2033
(8 years from now)
Active
US10513697 CO2 profile cultivation 17 Sep, 2032
(7 years from now)
Active
US9487809 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 14 Jan, 2032
(7 years from now)
Active
US10704071 Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 18 Aug, 2031
(6 years from now)
Active
US10011856 Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase 26 May, 2031
(6 years from now)
Active
US8460895 Method for producing recombinant proteins with a constant content of pCO2 in the medium 08 Aug, 2029
(4 years from now)
Active
US10906986 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(3 years from now)
Active
US7485704 Reducing protein A leaching during protein A affinity chromatography 08 Mar, 2025
(2 months from now)
Active
US9795672 Treatment with anti-VEGF antibodies 28 May, 2024
(6 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avastin's drug page


3. Herceptin

Herceptin is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10808037 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Herceptin's drug page


4. Lucentis

Lucentis is protected by 8 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10112994 Methods of producing two chain proteins in bacteria 05 Nov, 2035
(10 years from now)
Active
US9765379 Harvest operations for recombinant proteins 10 Mar, 2034
(9 years from now)
Active
US10421984 Methods for reducing norleucine misincorporation into proteins using a microorganism comprising a mutant metA allele 19 Sep, 2033
(8 years from now)
Active
US8383773 Protein product and method for reducing biomass-biomass interactions 13 Dec, 2023
(1 year, 14 days ago)
Expired
US6921659 Protease-deficient cells 17 Oct, 2023
(1 year, 2 months ago)
Expired
US9688775 System for antibody expression and assembly 31 Dec, 2022
(1 year, 11 months ago)
Expired
US6828121 Bacterial host strains 08 Jul, 2022
(2 years ago)
Expired
US6716602 Metabolic rate shifts in fermentations expressing recombinant proteins 01 Nov, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lucentis's drug page


5. Rituxan

Rituxan is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10759866 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(3 years from now)
Active
US10450379 Method for treating joint damage 14 Nov, 2026
(1 year, 10 months from now)
Active
US10654940 Method for treating joint damage 14 Nov, 2026
(1 year, 10 months from now)
Active
US7976838 Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor 30 Jun, 2025
(6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rituxan's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Xolair

Xolair is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12030959 Anti-IgE antibody therapy for multiple food allergies 20 Jul, 2043
(18 years from now)
Active
US11987637 Prevention of disulfide bond reduction during recombinant production of polypeptides 08 Jul, 2028
(3 years from now)
Active
US10034940 High concentration antibody and protein formulations 04 Nov, 2025
(10 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xolair's drug page